Parkinson’s Disease (PD) is a chronic and progressive neurological disorder, that affects a person's movement, balance, and coordination. It is related to a deficiency of the neurotransmitter dopamine, which is responsible for transmitting signals from the brain to the rest of the body. Risk factors for PD include aging, genetic predisposition, family history, and environmental exposures. Symptoms of Parkinson’s usually appear gradually, and can worsen over time. Common symptoms include shaking, rigidity, slow movement, difficulty with walking, and impaired balance. In some cases, speech may be affected, and depression can also be a symptom. In its early stages, treatment is typically symptomatic, meaning it focuses on alleviating the symptoms of the disease. Medication is one possible treatment, and these drugs typically act to increase dopamine levels in the brain. In addition to medications, physical therapists may be used to help maintain mobility and coordination. Sometimes, treatments such as deep brain stimulation or even surgical operations may be recommended. While there is no cure for Parkinson’s, early diagnosis is key to a successful treatment plan and improved quality of life. It is important for people with Parkinson’s to take part in regular physical activity, and other forms of exercise, to help maintain mobility and improve balance. In addition, people with PD should pay close attention to their diets and nutritional needs to ensure they get the nutrients they need. Support from family and friends is also important, and many people with Parkinson’s turn to support groups to get specialized advice and guidance.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States